In addition, similar results were shown that CRC patients in pathological stages III + IV had poorer progosis with lower E2F2 expression, including OS (HR = 0.48, 95% CI = 0.28-0.83, p = 0.008, Supplememtary Figure S2G), PFI (HR = 0.59, 95% CI = 0.37-0.94, p = 0.025, Supplememtary Figure S2H) and DSS (HR = 0.45, 95% CI = 0.24-0.84, p = 0.013, Supplememtary Figure S2I). The gene discussed is E2F2; the disease is colorectal carcinoma.